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RISPR-Cas systems are defense mechanisms present in
many bacteria and most archaea that provide RNA-guided
immunity against genetic invaders such as bacteriophages
and plasmids1,2. CRISPR-Cas systems can be divided in two
classes and six types based on their composition and the presence
of specific CRISPR-associated (cas) genes. Type III systems are
characterized by the presence of the signature protein Cas10 in
their multisubunit CRISPR RNA (crRNA)-guided effector com-
plexes, termed Csm complexes in subtypes III-A and III-D, and
Cmr complexes in subtypes III-B and III-C3. These complexes
directly recognize invader-derived RNA transcripts and harbor
two target-dependent nuclease activities, whereby Cas10 subunit
(also known as Csm1 or Cmr2) is allosterically activated to
degrade single-stranded DNA in a sequence non-specific manner
using its HD domain, while the Csm3/Cmr4 subunits cleave the
bound RNA in a sequence-specific manner4–10.
Additionally, target RNA binding activates the Palm domain of
the Cas10 subunit of the Csm/Cmr complexes to convert ATP
into cyclic oligoadenylate (cOA) second messengers of various
sizes, which in turn allosterically activate CRISPR-associated
Rossmann-fold (CARF) domain-containing effector proteins
including Csm6/Csx1 ribonucleases11–14. The type III CRISPR-
Cas systems found in different organisms have been shown to
produce different cOA species; whereas Streptococcus thermo-
philus and Enterococcus italicus generate cyclic hexa-AMP (cA6),
Thermus thermophilus, Sulfolobus islandicus or Sulfolobus solfa-
taricus produce cyclic tetra-AMP (cA4)11–14. Upon activation, the
RNase activity of Csm6/Csx1 enzymes, catalyzed by their ‘higher
eukaryotes and prokaryotes nucleotide binding’ (HEPN)
domains, provides an auxiliary interference mechanism to facil-
itate invader clearance and may induce dormancy or cell death.
Previous studies demonstrated its requirement for efficient
in vivo immunity, specifically when targeting late genes13,15–17. In
some type III CRISPR-Cas systems, cOA signaling is terminated
by standalone CARF domain-containing ring nucleases, proteins
able to degrade cA4 to yield linear adenosine tetra- and dinu-
cleotides18. Furthermore, recent studies have shown that some
Csm6-family enzymes can also intrinsically catalyze cOA degra-
dation and thus possess a self-inactivation mechanism19,20.
Although Csm6/Csx1 proteins that are activated by cA4 have
been recently characterized20,21, the molecular mechanisms of
cA6-dependent Csm6 RNases remain elusive. In this study, we
show that the type III CRISPR-associated RNase Csm6 from
Enterococcus italicus (EiCsm6), which is activated by cA6, pos-
sesses an intrinsic cA6 degradation activity mediated by its CARF
domain. Our crystal structure of EiCsm6 in complex with a non-
degradable cA6 mimic, together with supporting biochemical and
functional studies, reveal the mechanisms of cA6 sensing and
degradation, as well as cA6-mediated allosteric activation of
EiCsm6. These results provide a mechanistic framework for
understanding the function of CARF domain-containing effector
RNase in the context of CRISPR-Cas immunity.
Results
The CARF domain of Csm6 is a ring nuclease. We previously
showed that the ribonuclease Csm6 associated with the type III
CRISPR-Cas system from Enterococcus italicus is activated by
cyclic hexa-AMP (cyclic hexa-adenylate, cA6)22. To test whether
EiCsm6 is capable of degrading cA6, we analyzed reaction mix-
tures containing cA6 and wild-type (WT) EiCsm6 using liquid-
chromatography-mass spectrometry (LC-MS), revealing that cA6
was efficiently degraded to yield a mixture of products, including
a species with a m/z ratio of 986.1, matching that of linear tri-
AMP carrying a 2’,3’-cyclic phosphate group (Supplementary
Fig. 1). cA6 was also efficiently degraded in the presence of
RNase-deficient Csm6 containing a point mutation in the HEPN
active site (H377A), excluding the possibility that the degradation
is catalyzed solely by the HEPN domain (Supplementary Fig. 1).
Corroborating these results, a cA6 sample pre-incubated in
the presence of WT EiCsm6 protein was almost inactive in
stimulating the RNase activity of WT EiCsm6 in a fluorogenic
ribonuclease activity assay, indicative of cA6 degradation (Sup-
plementary Fig. 2a, b). Preincubation of cA6 with EiCsm6 con-
taining inactivating mutations in the HEPN domain (R372A/
N373A/H377A, herein referred to as dHEPN) resulted in partial
degradation of cA6 and reduced activation of WT EiCsm6, as did
pre-incubation with EiCsm6 containing a mutation (T114A) in
the conserved CARF domain motif. In contrast, preincubation
with EiCsm6 containing mutations both in the HEPN RNase
active site and in the CARF domain did not result in cA6
degradation (Supplementary Fig. 2b). Together, these experi-
ments indicate that although the RNase activity of the HEPN
domain contributes to cA6 degradation, the CARF domain of
EiCsm6 is intrinsically capable of catalyzing cA6 degradation.
Crystal structure of Csm6 bound to cA6 mimic. The catalytic
mechanism of cOA degradation by ring nucleases proceeds
through a nucleophilic attack of the ribose 2′-hydroxyl to generate
a 2′,3′-cyclic phosphate product19. Consistent with this, 2′,2′′,2′′′,
2′′′′,2′′′′′,2′′′′′′-hexa-F-c-hexa-dAMP (cFA6), a cA6 mimic con-
taining 2’-fluoro modifications in all positions, was resistant to
degradation yet still capable of allosterically activating EiCsm6,
albeit more weakly than cA6 (Supplementary Fig. 3a–c). The
half-maximal concentration (EC50) of cFA6 was determined to be
170 nM, ~50-fold higher than that of cA611, likely due to weaker
binding resulting from the 2’-fluoro modifications (Supplementary
Fig. 3d).
To gain structural insights into the mechanism of cA6 binding,
we co-crystallized EiCsm6 with cFA6 and determined the
structure of the complex at a resolution of 2.4 Å (Supplementary
Table 1). The structure reveals that EiCsm6 adopts the canonical
homodimeric architecture of Csm6/Csx1 enzymes, with extensive
dimerization interfaces between the CARF and HEPN domains.
A single molecule of cFA6 is bound within a conserved pocket
spanning the dimer interface of the CARF domains (Fig. 1,
Supplementary Fig. 4a), as predicted by earlier structural studies
of Thermus thermophilus Csm623, and recent structures of
Thermococcus onnurineus (ToCsm6) and Sulfolobus islandicus
(SisCsx1) proteins bound to c-tetra-AMP20,21. The cFA6 ligand
exhibits 2-fold rotational symmetry coincident with the 2-fold
symmetry axis of the EiCsm6 homodimer, with nucleotides A2-
A4 binding to one EiCsm6 protomer, and A1 and A5–A6 to the
other, and is surrounded by CARF domain loops comprising
residues 10–21, 39–41, 76–82, 111–116, and 137–139 (Supple-
mentary Fig. 4b). The 2’-fluoro ribose moieties adopt the C2’-
endo conformation in all positions, while the adenine bases adopt
the syn conformation in nucleotides A1/A4 and A2/A5, and
anti in A3/A6. Structural comparisons of the EiCsm6-cA6,
ToCsm6-cA4, and SisCsx1-cA4 complexes indicate that nucleo-
tides A1/A4 and A3/A6 in the EiCsm6 structure are accom-
modated similarly to their respective counterparts in the ToCsm6
and SisCsx1 structures, binding in structurally analogous (but
only partially conserved) pockets in the CARF domains, while
nucleotides A2/A5 occupy distinct sites at the CARF domain
interface (Supplementary Fig. 5).
cA6 sensing by the Csm6 CARF domain. The EiCsm6-cFA6
structure reveals that the ligand is recognized by an extensive
network of ionic and hydrogen-bonding interactions with
both the ribose-phosphate backbone and the adenine bases
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15334-5
2 NATURE COMMUNICATIONS |         (2020) 11:1596 | https://doi.org/10.1038/s41467-020-15334-5 | www.nature.com/naturecommunications
(Supplementary Fig. 4b, Supplementary Fig. 6). The bases of
nucleotides A1/A4 are inserted into a deep pocket and are
recognized via hydrogen-bonding interactions with the side chain
of Arg173 and the backbone carbonyl of Asp19, while A2/A5 and
A3/A6 interact with the side chains of Glu80 and Thr39/Ser41,
respectively (Fig. 2a, b). In turn, Gln116 forms a hydrogen bond
with the phosphodiester group connecting A2/A5 and A3/A6
(Fig. 2c). Alanine substitution of a subset of conserved residues
involved in cA6 binding, including Asn10, Thr114 and Gln116
(Supplementary Fig. 6), resulted in the reduction or near-
complete loss of cA6-dependent RNase activity, confirming the
importance of these residues for cA6 sensing (Fig. 2d).
In previous studies, we showed that the RNase activity of Csm6
in vivo depends on its allosteric activation by cyclic oligoadeny-
lates and demonstrated the compatibility between EiCsm6 and
the Staphylococcus epidermidis Type III Cas10–Csm complex22.
To validate our structural insights into cA6 sensing, we tested the
in vivo activity of wild-type and CARF domain mutant EiCsm6
proteins when co-expressed with the S. epidermidis type III
CRISPR-Cas system lacking DNase activity in the HD domain of
the Cas10 subunit (dHD) and an inducible RNA target. Target-
induced activation of WT EiCsm6 triggered growth arrest due to
its collateral RNase activity, which was dependent on the presence
of a targeting spacer in the CRISPR array, as shown previously for
S. epidermidis Csm617. In contrast, EiCsm6 mutants in which
specific residues involved in cA6 sensing were substituted with
alanine either did not cause growth arrest or impeded growth
only weakly, thus validating the importance of the CARF domain
residues for cA6 sensing and Csm6 activation in vivo (Fig. 2e).
Mechanism of autocatalytic cA6 degradation. The EiCsm6-
cFA6 structure provides insights into the mechanism under-
pinning cA6 degradation. As a consequence of the C2’-endo
ribose pucker in A6/A3 and the positioning of A1/A4 in its
binding pocket, the A6–A1 (and A3–A4) dinucleotide is forced
into a conformation favoring an in-line nucleophilic attack of the
A6/A3 2’-hydroxyl group onto the downstream scissile phos-
phodiester group to form a 2’,3’-cyclic phosphate trinucleotide
product (Fig. 3a). Whereas the 2’-fluoro group of A6/A3 (and,
presumably, the 2’-hydroxyl in cA6) is in hydrogen-bonding
contact with the backbone amide group of Asn10, the scissile
phosphodiester group is stabilized by hydrogen-bonding inter-
actions with the backbone amide group and the side chain of
Thr11. Thus, cA6 degradation by EiCsm6 seems to be mediated
primarily by steric factors that force the ligand to adopt a con-
formation compatible with in-line nucleophilic substitution and
does not involve deprotonation of the attacking nucleophile or
protonation of the leaving group by acid–base catalysis, as pos-
tulated for ring nucleases and other Csm6/Csx1 enzymes in
previous studies18–20. To verify the functional role of Thr11 in
cA6 degradation, we compared the cA6-dependent RNase
activities of WT and T11A EiCsm6 proteins. The T11A EiCsm6
protein retained the ability to be allosterically activated by cA6
in vitro (Fig. 2d), although the mutation caused only a weak
growth arrest phenotype in vivo (Fig. 2e), presumably because
the cA6 levels generated by the Cas10–Csm complex upon target
induction were insufficient to activate T11A EiCsm6 due to
partially compromised cA6 binding. The T11A EiCsm6 protein
was impaired in cA6 degradation, as indicated by a pre-
incubation experiment (Supplementary Fig. 7a) and confirmed
by LC-MS analysis (Supplementary Fig. 7b). Additionally, the
T11A EiCsm6 protein displayed sustained in vitro RNase activity
in the presence of 500 nM cA6, as compared to WT Csm6,
further indicating that it is deficient in cA6 degradation (Fig. 3b).
Collectively, these results suggest that cA6 degradation by the
CARF domain of EiCsm6 intrinsically limits the sequence non-






















Fig. 1 Cyclic hexaadenylate recognition by EiCsm6. a, b Overall structure of EiCsm6 homodimer bound to cFA6, shown in two orientations (a: side view of
the EiCsm6 homodimer; b: view of the cFA6 binding site at the CARF domain interface). The EiCsm6 homodimer is shown in cartoon representation (with
protomers colored light and dark blue). cFA6 is depicted in sphere format. c Zoom-in view of the cA6 binding site at the CARF domain interface of EiCsm6,
showing a 2mFO–DFC composite omit map, contoured at 1.0 σ and displayed within a radius of 2.2 Å around cFA6.
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specific RNase activity of the enzyme’s HEPN domain, which
might prevent self-toxicity and contribute to the termination of
the CRISPR immune response in vivo. To test this hypothesis, we
examined the effect of expressing WT or T11A EiCsm6 in the
presence of a S. epidermidis Cas10–Csm complex that was defi-
cient in target RNA degradation due to an inactivating mutation
in the Csm3 subunit (D32A, dCsm3), which results in sustained
production of cA6. At low levels of target induction, WT EiCsm6
was unable to cause growth arrest (Fig. 3c). In contrast, the T11A
EiCsm6 mutation resulted in a strong growth inhibition phe-
notype, indicating that the loss of ring nuclease activity in the
CARF domain results in the hyperactivation of EiCsm6.
cA6-dependent activation mechanism of Csm6. Owing to the
homodimeric architecture of Csm6 enzymes, their HEPN nuclease
domains form a composite RNase active site at the domain inter-
face23. In the EiCsm6-cFA6 structure, the site is occupied by a
sulfate ion originating from the crystallization solution, acting as a
mimic of the scissile phosphate in an RNA substrate (Fig. 4a). The
anion is contacted by salt-bridge interactions with Arg372 and
flanked by a pair of His377 side chains, which are part of the R-X4-
H HEPN domain motif and predicted to elicit acid–base catalysis
based on homology with other HEPN-domain RNases24 (Supple-
mentary Fig. 8a, b). The disposition of the active site residues is
similar as in the activated-state structures of both RNase L and cA4-
recognizing Csm6/Csx1 RNases ToCsm6 and SisCsx120,21,25,26,
indicating that the HEPN domains adopt the activated conforma-
tion in the EiCsm6–cFA6 complex.
Some Csm6 enzymes display basal HEPN-dependent RNase
activity in the absence of cOA ligands15,23,27, suggesting that their
HEPN domains sample a conformational equilibrium between
activated and inactive states. This is supported by the observation
that the conformations of apo-ToCsm6 and apo-SisCsx1 are
nearly identical to their respective cA4-bound structures20,21,
suggesting that they may represent the activated state. Based on
these considerations, an allosteric activation model for EiCsm6
can be envisioned (Fig. 4b). In the absence of cA6, EiCsm6 exists
in a dynamic conformational equilibrium between inactive and
activated forms, with the inactive form(s) being predominant.
The HEPN domain active center and the CARF domain cA6
binding site are allosterically coupled. cA6 binding to the CARF
domain interface preferentially stabilizes the activated form, in
which the HEPN domain histidine residues are properly oriented
to catalyze RNA degradation by an acid–base mechanism. While
bound to cA6, the CARF domains act as a ring nucleases whose
slow activity converts cA6 into two molecules of 2’,3’-cyclic
phosphate-terminated tri-AMP and triggers product dissociation.
This leads to termination of the HEPN domain RNase activity by
destabilization of the activated conformation. The biological
activity of Csm6 enzymes is thus controlled by the interplay of the
HEPN domain RNase activity and the slow, cis-acting ring
nuclease activity of the CARF domain.
Discussion
In sum, the structural and biochemical studies presented in this
































































Fig. 2 The CARF domain of EiCsm6 recognizes cA6. a–c Protein-cFA6 interactions. EiCsm6 is depicted in cartoon representation; cFA6 is shown as sticks.
Hydrogen-bonding interactions are represented as black dotted lines. d Fluorogenic RNase activity assay of CARF domain mutants of EiCsm6 (0.5 nM) in
the presence of 10 nM cyclic-hexa-AMP (cA6). AU, arbitrary units. e Growth curves (optical density at a wavelength of 600 nm) of Staphylococcus aureus
strains harboring pTarget and pCRISPR plasmids. The pCRISPR plasmid expresses wild-type or CARF domain mutants of EiCsm6 and the Staphylococcus
epidermidis Cas10–Csm effector complex containing an inactivating point mutation in the HD domain of Cas10. Data points in d, e represent the mean of
three replicates; error bars represent the standard error of the mean (s.e.m.). Source data are provided as a Source Data file.
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for cA6 sensing, allosteric activation, and autocatalytic inactiva-
tion in Csm6 enzymes. We previously demonstrated the allosteric
activation of EiCsm6 by cA6 generated by the Palm domain of
Cas10 upon RNA target recognition22. We now show that the
CARF domain of EiCsm6 responsible of cOA sensing also cata-
lyzes the degradation of the substrate, acting as an intrinsic timer
that limits the non-specific RNase activity of the HEPN domain.
The generation of cA6 degradation products in the presence of a
HEPN-domain catalytic mutation proves that the CARF domain
of EiCsm6 harbors a ring nuclease activity, although the RNase
activity of the HEPN domain also contributes to cOA degrada-
tion, as suggested by other studies20. By degrading cOA second
messengers in cis, the ring nuclease activity of Csm6 enzymes
thus complements the RNase activity of the Cas10 effector
complex that mediates target RNA degradation, which results in
the termination of cOA synthesis by the Cas10 Palm domain.
The structure of EiCsm6 bound to cFA6 reveals the cOA
recognition and degradation mechanisms. The homodimeric
architecture of EiCsm6 results in the formation of a high-
affinity cA6 binding site at the CARF domain interface. Based
on the structure, we identify several residues involved in cA6
recognition and confirm their role in second messenger sensing
in vitro and in vivo. We additionally show that perturbation of
the ring nuclease activity of the CARF domain (by targeting the
CARF domain residue Thr11 involved in transition state sta-
bilization) results in a hyperactive Csm6 RNase with a slower
inactivation profile. The high degree of conservation of the
residues involved in cOA binding and degradation suggests
that our proposed mechanisms likely apply to other cA6-
specific Csm6 proteins (Supplementary Fig. 6). Notably, the
cA6 degradation mechanism of EiCsm6 does not involve
acid–base catalysis, contrary to mechanisms postulated for
other Csm6/Csx1 enzymes and ring nucleases18–20. Finally, the
superposition of the EiCsm6 HEPN domains to other HEPN-
domain nucleases indicates that EiCsm6 bound to cFA6 is
stabilized in an activated state, pointing to a mechanism for
cOA-dependent allosteric activation of Csm6/Csx1 proteins
relying on conformational selection.
In the context of CRISPR-Cas immunity, self-degradation of
cOA by Csm6/Csx1-family RNases likely provides a mechanism
for temporal control of their collateral RNase activity. Together
with the target-directed RNase activity of the Cas10 effector
complex, which leads to target cleavage and cessation of cOA
production, this ensures termination of the antiviral response
upon invader clearance. In some type III CRISPR-Cas systems,
the ring nuclease activity may limit the self-toxicity of Csm6
enzymes, particularly in systems that do not possess standalone
ring nucleases. Consistent with this, we demonstrate that
impairment of the CARF domain ring nuclease activity in
EiCsm6 results in its hyperactivation and CRISPR self-toxicity.
Finally, the widespread occurrence of type III CRISPR-Cas
systems, as well as the recently discovered bacterial cGAS/
DncV-like nucleotidyltransferase (CD-NT) enzymes that syn-
thesize diverse cyclic di- and trinucleotides28, combined with
the diversity of their downstream effectors29,30, suggests that
cyclic oligonucleotide-dependent signaling is an important
aspect of prokaryotic genome defense systems and awaits fur-















































Fig. 3 The CARF domain of EiCsm6 catalyzes cA6 hydrolysis. a Zoom-in view of nucleotides A1 and A6 of cFA6 bound to the EiCsm6 CARF domain.
Residues implicated in the cleavage are represented as sticks; hydrogen-bonding interactions are depicted as black dotted lines. The red arrows represent
the proposed reaction mechanism of cA6 cleavage involving nucleophilic attack of the 2’-hydroxyl group of A6 onto the phosphodiester group connecting
A6 and A1. b RNase activity assay comparing the activity of WT and T11A EiCsm6 proteins in the presence of 500 nM cA6. The black arrows represent
spike-ins of 0.8 pmol of RNaseAlert substrate at 5 min intervals. AU, arbitrary units. c Growth curves (optical density at a wavelength of 600 nm) of
Staphylococcus aureus strains harboring pTarget and pCRISPR plasmids. The pCRISPR plasmid expresses wild-type or CARF domain mutants of EiCsm6 and
the Staphylococcus epidermidis Cas10–Csm effector complex containing an inactivating point mutation in the Csm3 subunit (D32A; dCsm3). Data points in
b, c represent the mean of three replicates; error bars represent the standard error of the mean (s.e.m.). Source data are provided as a Source Data file.
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Methods
Protein expression and purification. The gene sequence of EiCsm6 was amplified
from genomic DNA (Enterococcus italicus DSM-15952) by PCR and cloned into a
1B vector (Addgene 29653) using ligation-independent cloning resulting in con-
structs carrying an N-terminal hexahistidine tag followed by a tobacco etch virus
(TEV) protease cleavage site. Point mutations were introduced by inverse PCR and
verified by DNA sequencing. EiCsm6 and its mutants were purified similarly as
described before11. Briefly, EiCsm6 was expressed in BL21 Star (DE3) E. coli cells
grown in LB medium by induction with 0.5 mM IPTG at 18 °C for 16 h. Harvested
cells were resuspended in lysis buffer (20 mM HEPES pH 7.5, 500 mM KCl and
5 mM imidazole), lysed by sonication, and the lysate was clarified at 20,000 × g for
30 min. The clarified lysate was loaded onto a 5 ml Ni-NTA HisTrap (GE Life
Science) column. The column was washed with lysis buffer supplemented with
increasing concentrations of imidazole and the protein was eluted with 20 mM
HEPES pH 7.5, 500 mM KCl and 250 mM imidazole. The elution fractions were
pooled and diluted with SEC buffer (20 mM HEPES pH 7.5, 500 mM KCl) to a final
imidazole concentration of 50 mM. To remove the hexahistidine tag, the sample
was incubated at 4 °C for 16 h in the presence of His-tagged TEV protease. The
sample was then reapplied to the Ni-NTA affinity column to remove uncleaved
protein and the protease. In a final step, the protein was purified by size exclusion
chromatography in SEC buffer using a Superdex S200 16/60 column (GE
Healthcare). Csm6-containing fractions were identified by SDS-PAGE and con-
centrated using a 100,000 Da molecular weight cut-off centrifugal filter (Merck
Millipore) to a final concentration of approximately 20 mgml−1 and stored at
−80 °C until use.
X-ray crystallography. Crystals of EiCsm6 were initially grown in the presence of
cA6 (2-fold molar excess) using the hanging drop vapor diffusion method. 50 μM
of EiCsm6 and 100 μM of cA6 were mixed 1:1 (1 μl+ 1 μl) with reservoir solution
containing 100 mM Bis Tris Propane pH 5.5–6.5, 20–35% PEG3350 and 200 mM
sodium citrate. Crystals were cryoprotected with reservoir solution supplemented
with 25% glycerol and flash cooled in liquid nitrogen. Data were collected at the
beamline PXIII of the Swiss Light Source (Paul Scherrer Institute, Villigen, Swit-
zerland) and processed with XDS31. The crystals belonged to space group P212121
and contained one Csm6 dimer per asymmetric unit. Data analysis using phenix.
xtriage32 indicated the presence of a large off-origin peak (68.7% of the origin
value) in the Patterson function, indicative of translational non-crystallographic
symmetry (NCS). Experimental phases were obtained by the single isomorphous
replacement-anomalous scattering (SIRAS) method in autoSHARP33 using native
data and a single-wavelength anomalous dispersion (SAD) dataset obtained from a
crystal soaked with 5 mM thimerosal for 5 min and measured at the Hg L-III
absorption edge (wavelength of 1.00767 Å). Density modification of experimental
phases in AutoSHARP resulted in an interpretable map which was used for initial
model building of the EiCsm6 homodimer. Notably, there was no indication in the
density maps for the presence of cA6 bound to the CARF domain, suggesting that
the ligand underwent degradation in situ. The refinement of the atomic model
stalled at a Rfree value of ~40%, presumably due to high degree of translational
pseudosymmetry, and could not be completed.
EiCsm6 crystals bound to cFA6 (synthesized by Biolog Life Science Institute
GmbH & Co. KG) were grown in drops containing 120 μM EiCsm6 and 288 μM
cFA6 equilibrating against a reservoir solution containing 100 mM HEPES pH 7.5,
1.6 M ammonium sulfate and 25 mM lithium perchlorate. The crystals diffracted to
a resolution of 2.4 Å, belonged to space group P1, and contained four EiCsm6
homodimers, related by translational non-crystallographic symmetry, in the
asymmetric unit. A native dataset was collected at the beamline PXIII of the Swiss
Light Source and processed with autoproc34. Phases were calculated by molecular
replacement in Phaser35, as implemented in Phenix, using the atomic model of the
EiCsm6 protomer obtained by experimental phasing. The resulting electron density
map showed clear features corresponding to cFA6 bound to the dimeric interface
of the CARF domains of EiCsm6. The atomic model of the EiCsm6-cFA6 complex
was completed by iterative building in Coot36 and refined with Phenix.refine37
(Supplementary Table 1). A 2mFO–DFC composite omit38 map was calculated in
Phenix using default parameters.
Ribonuclease activity assays. The RNase activity of EiCsm6 and its activation
was assayed using a fluorogenic substrate similarly as described before22. Briefly,
cA6, cFA6 (both synthesized by Biolog Life Science Institute GmbH & Co. KG), or
supernatants from cA6 degradation reactions were incubated with EiCsm6 or its
mutants in 10 mM HEPES pH 7.5 and 50 mM KCl in a total volume of 100 μl. The
reaction was started by addition of 2 pmol (0.8 pmol for the spike-in experiment) of
RNaseAlert substrate (Integrated DNA Technologies). Fluorescence signal (exci-
tation at 490 nm, emission at 520 nm) was measured over time using a PHERAstar
FSX (BMG Labtech) multimodal plate reader. All experiments were done in tri-
plicates and the data points represent the mean ± standard error of the mean
(s.e.m.). Assays comparing EiCsm6 activation by cA6 and cFA6 (Supplementary
Fig. 3) used 100 nM (final concentration) of ligand and 1 nM of WT EiCsm6.
Experiments to compare the effect of CARF domain mutations (Fig. 2d) used
10 nM of cA6 and 0.5 nM of each EiCsm6 mutant. For the RNase substrate spiking
experiment (Fig. 3b), WT EiCsm6 or the T11A mutant (10 nM final concentration)
was mixed with cA6 (500 nM final concentration) and 0.8 pmol of RNaseAlert
substrate at the start of the reaction, and additional RNaseAlert substrate
(0.8 pmol) was spiked-in every 5 min.
For the pre-incubation assay of cA6 with EiCsm6 or its mutants
(Supplementary Figs. 2 and 7), 100 nM of protein were incubated with 1 μM of cA6
with for 60 min at 37 °C in a total volume of 100 μl. The reaction was stopped by
incubating the sample at 95 °C for 5 min and denatured EiCsm6 was removed by
























EiCsm6 HEPN active site
Fig. 4 Model of cA6-mediated allosteric activation mechanism of Csm6
RNases. a Zoom-in view of the HEPN domain ribonuclease active site in
EiCsm6. The conserved R372, N373, H377 residues of the HEPN catalytic
motif, and additionally R274, are represented as sticks. Electron density,
interpreted as a sulfate ion (depicted as 2mFO–DFC composite omit map,
contoured at 1.0 σ and displayed within a radius of 2.2 Å), is located within
hydrogen bonding distance of H377, likely mimicking the scissile phosphate
group of an RNA substrate. b Schematic model of the cA6-mediated
allosteric activation mechanism of Csm6 enzymes.
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(or 20 nM of cA6 as positive control) were added to 2 nM of WT EiCsm6 for
activity assay using RNaseAlert as described above. The experiments were done in
parallel and the results are presented in two figures for clarity, with the same set of
controls. For the pre-incubation assay with cA6 or cFA6 (Supplementary Fig. 3),
1 μM of WT EiCsm6 was incubated with 10 μM of cA6 or cFA6 for 60 min at 37 °C
in a total volume of 100 μl. After inactivation, 1 μl of the reaction supernatant (or
0.1 μM cA6 as positive control) were used with 20 nM WT EiCsm6 in the
RNaseAlert activity assay.
Csm6 toxicity growth curves. Growth curves from EiCsm6 interference against
pTarget was performed as previously described17. Briefly, overnight cultures
containing plasmids pTarget and pCRISPR (pJTR366, pJTR367, pJTR368,
pJTR369, pJTR417, pJTR422, or pGG-BsaI-R for the dHD loss-of function
experiments, and pJTR413, pJTR415, or pGG-BsaI-R for the gain-of-function
experiments) were diluted and normalised for optical density (OD) measured at a
wavelength of 600 nm. Cells were then seeded in a 96 well plate and target
transcription was induced with anhydrous tetracycline (12.5 ng ml−1 for the
experiment shown in Fig. 2e, or 5 ng ml−1 for the experiment shown in Fig. 3c).
OD readings were then obtained every 10 min with a microplate reader (TECAN
Infinite 200 PRO).
Molecular cloning for in vivo assays. pJTR366 was generated by amplifying
pJTR109 with JTR632 and JTR633, and pJTR179 with JTR915 and JTR918), and
combining the PCR products by Gibson assembly39. pJTR367 was generated by
amplifying pJTR109 with JTR632 and JTR633, and pJTR181 with JTR915 and
JTR918), and combining the PCR products by Gibson assembly. pJTR368 was
generated by first making pJTR355 (by amplifying pJTR179 with JTR223 and
JTR924, and with JTR921 and JTR224, and combining the PCR products by
Gibson assembly), and them amplifying pJTR109 with JTR632 and JTR633 and
pJTR355 with JTR915 and JTR918, and combining the PCR products by Gibson
assembly. pJTR369 was generated by first making pJTR356 (by amplifying pJTR179
with JTR223 and JTR924, and by JTR921 and JTR224, and combining the PCR
products by Gibson assembly), and amplifying pJTR109 with JTR632 and JTR633,
and pJTR356 with JTR915 and JTR918, and combining the PCR products by
Gibson assembly. pJTR417 was generated by amplifying pJTR366 with W852 and
JTR967, and with W614 and JTR966, and combining the PCR products by Gibson
assembly. pJTR422 was generated by amplifying pJTR366 with W852 and
JTR969, and with W614 and JTR968, and combining the PCR products by Gibson
assembly. pJTR413 was generated by amplifying pJTR360 with W852 and PS466,
and with W614 and PS465, and combining the PCR products by Gibson assembly.
pJTR415 was generated by amplifying pJTR366 with W852 and PS466, and with
W614 and PS465, and combining the PCR products by Gibson assembly. pGG-
BsaI-R was described previously40. The plasmids and primers used for in vivo
assays are described in Supplementary Tables 2 and 3 respectively.
EC50 analysis for cFA6. RNase activities were measured for reactions containing
5 nM of EiCsm6 supplemented with the indicated cFA6 concentrations. Initial
velocities were calculated during the first 100 s and were plotted against cFA6
concentrations in GraphPad and fitted by using a nonlinear regression analysis
using the log(dose)-versus-response relationship, assuming a variable Hill
coefficient.
LC-MS analysis. The degradation of cA6 or cFA6 was assayed by incubating
equimolar amounts (final concentration of 25 μM) with WT EiCsm6 or the
H377A mutant at 37 °C for 1 h in a total volume of 40 μl for Supplementary
Figs. 1 and 3. For Supplementary Fig. 6a, 5 μM of EiCsm6 T11A/R372A/N373A/
H377A or R372A/N373A/H377A were incubated with 50 μM of cA6 at 37 °C for
30 min. The reaction was stopped by incubating the sample at 95 °C for 5 min.
The denatured protein was removed as described above. LC-MS analysis was
performed on an Agilent 1200/6130 LC-MS equipped with a Waters Acquity
UPLC OST C18 column (2.1 × 50 mm, 1.7 μm) at 65 °C. 30 μl of sample were
injected. Eluent A was aqueous hexafluoroisopropanol (0.4 M) containing trie-
thylamine (15 mM). Eluent B was methanol. Elution parameters are provided in
Supplementary Table 4.
cFA6 synthesis. All reagents and solvents for chemical operations were of ana-
lytical grade or the highest-purity grade available from commercial suppliers.
Solvents for chromatographic operations were specified as analytical grade, HPLC-
grade, or gradient HPLC-grade. YMC*Gel SIL (6 nm, S-75 µm) was used for
preparative flash chromatography and TLC was performed with Merck 60
F254 silica gel plates. All chromatographic operations were performed at ambient
temperature. Evaporation of solvents was accomplished by rotary evaporation in
vacuo either with membrane pump vacuum or oil pump high vacuum with water
bath temperatures not exceeding 30–33 °C.
UV-spectra were recorded on a JASCO V-650 spectrometer in phosphate-
buffered aqueous solution (pH 7). Mass spectra were generated with a Bruker
Esquire LC 6000 spectrometer in the electrospray ionization mass spectrometry
(ESI-MS) mode with 50% water/49.5% methanol/0.5% NH3 (pH 9–10) as matrix.
Nuclear magnetic resonance (NMR) spectra were recorded with a 400MHz Bruker
Avance III HD and chemical shifts are expressed in parts per million (ppm).
Chemical shifts were referenced to the DMSO solvent signal, 2.50 ppm for 1H. 85%
phosphoric acid was used as external standard for 31P NMR spectra with 0 ppm.
All 31P NMR spectra were recorded with proton decoupling.
Analytical HPLC was performed using a VWR / Hitachi: L-7100 Pump; VWR /
Hitachi: L-7400 variable wavelength UV/Vis detector and VWR / Hitachi: D-7500
Integrator.
For the chemical synthesis, 2.3 mmol of cyanoethyl phosphoramidite 5’-DMTr-
2’-F-3’-CEP-N6-Bz-adenosine (ChemGenes, Wilmington, MA, USA, Cat. No.
ANP-9151) were used as starting material for the stepwise synthesis of the




3’-H-phosphonate-N6-Bz-adenosine with a standard oligonucleotide coupling
protocol41 with the following modifications: After initial phosphonate preparation
and after each coupling step with 1.4 eq. 5’-DMTr-2’-F-3’-CEP-N6-Bz-adenosine
and 2 eq. 5-ethylthio-tetrazole as coupling reagent the raw material was purified by
preparative flash chromatography on silica gel using a step-gradient of methanol in
dichloromethane. The final cyclization step and the release of protection groups
was performed according to a standard protocol41, leading to the raw product cFA6
after the evaporation of solvents. 100 mL water was added and the resulting
suspension was placed in an ultrasonic bath at room temperature for 15 min.
Afterward, additional 100 mL water was added followed by 3 extraction cycles with
200 ml chloroform each. The combined organic phases were extracted with 300 ml
water and the combined product-containing aqueous phase was filtered with a
0.45 µm regenerated cellulose (RC) filter and concentrated under reduced pressure.
The complex reaction mixture was initially purified by repeated preparative reversed
phase medium pressure liquid chromatography (MPLC). The product solution was
applied to a Merck LiChroprep®RP-18 column (15–25 µm; 450 × 50mm)
previously equilibrated with 100 mM triethylammonium formate (TEAF, pH 6.8)
in water. Elution was performed with a step-gradient of 3, 4, 6, 8, and 10% 2-
propanol, 20 mM TEAF (pH 6.8) in water. Subsequent purifications of product
containing fractions were accomplished by a Merck LiChroprep®RP-18 column
(15–25 µm; 450 × 25 mm) with 2-propanol as organic modifier. Final purifications
were performed by semi-preparative reversed phase HPLC with a YMC*GEL ODS-
A 12 nm column (10 µm; 250 × 16 mm), previously equilibrated with 100 mM
sodium dihydrogen phosphate (NaH2PO4) buffer (pH 6.8). Elution was performed
with a step-gradient of 8, 9, and 10% acetonitrile, 50 mM NaH2PO4 (pH 6.8) in
water. For desalting, cFA6 fractions of sufficient purity were applied to a Merck
LiChroprep® RP-18 column (15–25 µm; 450 × 25 mm), previously equilibrated
with water. The column was washed with water to remove excess TEAF or
NaH2PO4 buffer. Afterward, 2% 2-propanol in water was used to elute the desalted
cFA6. To generate the sodium salt form of cFA6, pooled product-containing
fractions were partially concentrated under reduced pressure and subsequently
applied to a Toyopearl™ SP-650M cation exchange column (65 µm; 100 × 10 mm)
Na+-form, previously regenerated with 2M sodium chloride and washed with
water. For elution the column was washed with water until no UV-absorbance was
detectable at 254 nm anymore. After filtration and careful evaporation under
reduced pressure, 36.65 µmol cFA6, sodium salt was isolated with a purity of
99.66% by HPLC (theoretical yield: 1.59%).
Compound name: 2’-,2’’-,2’’’,2’’’’,2’’’’’,2’’’’’’-hexadeoxy-2’-,2’’,2’’’,2’’’’,2’’’’’,2’’’’’’-
hexafluoro-cyclic hexaadenosine monophosphate (cFA6; 2’-,2’’,2’’’,2’’’’,2’’’’’,2’’’’’’-
hexa-F-c-hexa-dAMP), sodium salt
Formula (free acid): C60H66F6N30O30P6 (MW 1987.18 g/mol)
UV-Vis (water pH 7.0): λmax 259 nm; ε 81000.
ESI-MS pos. mode: m/z 1071 (M+H+ 7 Na)2+, m/z 1060 (M+H+ 6 Na)2+,
ESI-MS neg. mode: m/z 992 (M−H)2-, m/z 1986 (M−H)−.
1H NMR (400MHz, D2O) δ 8.12 (s, 6H), 7.91 (s, 6H), 6.18 (dd, J= 15.7, 3.2 Hz,
6H), 5.54 (ddd, J= 51.1, 4.7, 3.3 Hz, 6H), 5.08-4.95 (m, 6H), 4.56 (s, 6H), 4.41–4.24
(m, 12H) ppm.
31P NMR (162MHz, D2O): δ −0.31 (s, 6P) ppm.
Analytical HPLC (Kromasil 100-10, RP-8 (10 µm; 250 × 0.4 mm)) 8%
acetonitrile, 25 mM NaH2PO4 buffer, pH 6.8; 1.5 mL/min; UV 260 nm: tRET
10.59 min.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available as Source Data file. The
atomic coordinates of EiCsm6 bound to cFA6 been deposited in the Protein Data Bank
(PDB) under accession code 6TUG.
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